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Significance and Impact of the Study: Antifungal lock therapy can be a potential therapeutic approach
to eradicate the intraluminal Candida biofilms; however, there is no approved lock strategy against fun-
gal species so far. The results of this study provide valuable evidence that nikkomycin Z acts synergisti-
cally in combination with caspofungin or micafungin against biofilms. In addition, this synergy was
more pronounced for micafungin combined with nikkomycin Z. Therefore, nikkomycin Z can be consid-
ered as a potential agent in antifungal lock therapy especially with micafungin against C. albicans or C.
parapsilosis biofilms.
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Abstract
Antifungal lock therapy has received significant interest in the last few years
because the frequently usage of intravascular devices is associated with an
increasing number of catheter-related bloodstream infections caused by Candida
species. Antifungal combinations with synergistic interaction can be a good
choice for antifungal lock therapy; therefore, interactions were examined between
two echinocandins (caspofungin and micafungin) and the chitin synthesis
inhibitor nikkomycin Z against Candida albicans and C. parapsilosis biofilms.
Susceptibility was evaluated using the XTT-based checkerboard microdilution
method, while the nature of interactions was assessed by calculating fractional
inhibitory concentration indices and using the Bliss independence model.
Mathematic-based evaluations were supplemented with fluorescent LIVE/DEAD
viability assay. The results obtained by statistical interaction analyses correlated
well with the viability assay. The tested echinocandins with nikkomycin Z caused
an extended cell death and the structure of the biofilm was sparse compared to
the control, especially for C. albicans. The findings support the simultaneous
usage of nikkomycin Z and caspofungin or micafungin in alternative therapies
such as the antifungal lock therapy.
Introduction
Candida albicans remains the most frequently isolated
fungal species from catheter-associated infections followed
by C. parapsilosis due to their high biofilm-forming ability
(Bassetti et al. 2013; Soldini et al. 2018; Monfredini et al.
2018). A previous study revealed that Candida biofilm
production is associated with significantly higher mor-
tality compared to patients with bloodstream infec-
tions caused by non-biofilm-forming Candida species
(Rajendran et al. 2016). Echinocandins are a group of
semisynthetic cyclic lipopeptides, which inhibit the syn-
thesis of b- glucan in the fungal cell wall via noncompeti-
tive inhibition of 1,3-b glucan synthase (Patil and
Majumdar 2017). They can be potential candidates for
anti-biofilm alternative therapies such as antifungal lock
therapy, where prolonged instillation of a solution con-
taining high concentration of antifungal agent is utilized
within and intravascular catheter (Walraven and Lee
2013). However, lock treatment can fail especially against
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C. parapsilosis biofilms due to the previously well-docu-
mented intrinsic fks mutation (Garcia-Effron et al. 2008).
Nikkomycin Z is a nucleoside-peptide, which inhibits
chitin synthesis by acting as competitive analogue of the
chitin synthase substrate UDP–N-acetylglucosamine (Kim
et al. 2002). In vitro synergistic interactions have been
already described with various antifungals including
echinocandins against Candida species; however, these
studies focused on exclusively planktonic forms (San-
dovsky-Losica et al. 2008; Szilagyi et al. 2012; Cheung and
Hui 2017); therefore, the potential synergistically effect of
nikkomycin Z with echinocandins against Candida bio-
films remains unclear.
To extend our knowledge about in vitro interactions,
we evaluated the effect of caspofungin and micafungin
combined with nikkomycin Z against C. albicans and C.
parapsilosis biofilms. We hypothesized that nikkomycin Z
exerts a synergistic interaction with the tested echinocan-
dins supporting the use of these combinations in the
above-mentioned antifungal lock therapy.
Results and discussion
Under planktonic conditions five out of six C. albicans
isolates were susceptible to the tested echinocandins based
on revised clinical laboratory standards institute break-
points (Pfaller et al. 2011). As expected, isolate DPL18
was resistant both to caspofungin and micafungin (mini-
mal inhibitory concentration was 2 mg l1 for caspo-
fungin, as well as for micafungin) (Pfaller et al. 2011).
For susceptible C. albicans clinical isolates, the planktonic
MICs ranged from 0015 to 003 mg l1, from 0015 to
006 mg l1, and from 4 to 8 mg l1 for caspofungin,
micafungin and nikkomycin Z respectively. Four out of
five planktonic clinical C. parapsilosis isolates were suscep-
tible to both echinocandins with a narrow range of MIC
values (between 1 and 2 mg l1), while isolate CP3
showed intermediate susceptibility (MIC of 4 mg l1)
both for caspofungin and micafungin (Pfaller et al. 2011).
The examined nikkomycin Z concentrations resulted
prominent inhibitory effect from 8 mg l1 concentration
against planktonic C. parapsilosis isolates. The variability
of the planktonic MICs across repetitions was low, the
difference between repetitions were within one dilution in
case of all isolates.
The median values of MIC for C. albicans and C. para-
psilosis biofilms are presented in Table 1. Similar to
planktonic forms, the variability of biofilm MIC between
repetitions were within one dilution in case of all isolates.
In case of echinocandin-susceptible C. albicans isolates,
nikkomycin Z resulted in 2- to 16-fold and 16- to 128-
fold decrease of the median MICs for caspofungin and
micafungin respectively. Moreover, nikkomycin Z median
MIC values showed 8- to 512-fold decrease in combina-
tion with caspofungin or micafungin against susceptible
C. albicans sessile cells. Nikkomycin Z exerted 64-fold
and 4-fold MIC value decrease against isolate DPL18 for
caspofungin and micafungin respectively. In case of C.
parapsilosis biofilms, the median MIC values observed for
caspofungin and micafungin in combination with nikko-
mycin Z demonstrated 2- to 4-fold and 2- to 64-fold
decrease for caspofungin and micafungin respectively. The
median MIC values of nikkomycin Z in combination with
echinocandins showed 2- to 512-fold reduction for C.
parapsilosis biofilms.
Table 1 summarizes the in vitro interactions between
the tested echinocandins and nikkomycin Z based on
FICI calculations and Bliss independence analysis. By
FICI, synergy between nikkomycin Z and caspofungin or
micafungin was observed against the majority of C. albi-
cans isolates (Table 1). An indifferent effect was noticed
exclusively for isolate CA2 and CA3 but these biofilms
had lower MIC values against caspofungin or micafungin
without nikkomycin Z (Table 1). The combination of
caspofungin and nikkomycin Z yielded an indifferent
interaction against all five C. parapsilosis isolates (FICI
0502-1). Of note, FICIs of three out of five isolates were
very close to threshold indicating synergy (FICI 0502–
0508) (Table 1). Based on FICI values, a striking syner-
gistic interaction was observed for four out of five C.
parapsilosis isolates after micafungin with nikkomycin Z
exposure (FICI 0017–05), which was confirmed by the
results of Bliss independence analysis (Table 1). Statisti-
cally significant synergy was revealed for most combina-
tions with caspofungin and micafungin both against
echinocandin-susceptible C. albicans clinical isolates and
the resistant strain using Bliss analysis (Table 1, Fig. 1a,
b). Although FICIs demonstrated indifferent interactions
between caspofungin and nikkomycin Z against C. parap-
silosis isolates, these interactions were synergistic for most
combinations using MacSynergy calculations (Table 1).
This discrepancy could be explained by the failure of FICI
determination, which is too subjective and sensitive to
experimental errors. The potential variability between var-
ious methods highlights the necessity to apply multiple
analytic approaches in case of examinations of drug-drug
interactions.
In accordance with FICI findings, highly significant
synergy was detected using Bliss model for combinations
of micafungin and nikkomycin Z against C. parapsilosis
biofilms (Fig. 1c,d). It is noteworthy that clear antagonis-
tic interactions were described for the tested species nei-
ther using FICI calculations nor using the Bliss
independence model (Table 1).
LIVE/DEAD viability staining revealed that micafungin-
exposed C. albicans and C. parapsilosis biofilms exhibited
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increased cell death in the presence of nikkomycin Z
(Fig. 2g,h) compared to untreated biofilms (Fig. 2a,b),
micafungin-exposed sessile populations (Fig. 2e,f) or nik-
komycin Z treated biofilms (Fig. 2c,d). Caspofungin
showed highly similar pattern to micafungin both alone
and in combination with nikkomycin Z. To confirm the
metabolic activity-based experiments and LIVE/DEAD
viability staining, the number of cultivable sessile cells
was determined by quantitative culturing of one-one rep-
resentative isolates from C. albicans (CA1) and C. parap-
silosis (CP1) on Sabouraud dextrose agar as in our
previous study (Nagy et al. 2018). The obtained CFU
count in echinocandin-nikkomycin Z combinations
showed significant CFU decrease (P < 005–001)
compared to cell number derived echinocandin-exposed
Candida sessile populations (data not shown).
Previous studies revealed the potential synergizing
effect of nikkomycin Z in combination with traditional
antifungal agents against Candida species (Sandovsky-
Losica et al. 2008; Szilagyi et al. 2012; Cheung and Hui
2017). However, these works examined exclusively the
anti-planktonic effect of these combinations and recently
there is no information about susceptibility of biofilms
formed by C. albicans or non-albicans species. A combi-
nation treatment with nikkomycin Z and an echinocandin
have several advantages such as the prevention of
echinocandin-induced paradoxical growth, which can















































































Figure 1 Effect of nikkomycin Z in combination with caspofungin (a and c) and micafungin (b and d) against Candida albicans (a and b) and Can-
dida parapsilosis (c and d) sessile cells of one-one representative isolate of C. albicans (CA1) and Candida parapsilosis (CP1) by MacSynergy II anal-
ysis. Peaks of positive values represent synergy, whilst negative values indicate antagonism at given concentrations (a and b: ( ) 60–80, ( ) 40–
60, ( ) 20–40, ( ) 0–20; ( ) and ( ) 20–0; c and d: ( ) 100–120, ( ) 80–100, ( ) 60–80; ( ) 40–60; ( ) 20–40; ( ) 0–20).
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against C. albicans or C. parapsilosis in antifungal lock
therapy (Melo et al. 2007; Shields et al. 2011). Further-
more, C. parapsilosis isolates have intrinsic reduced sus-
ceptibility to echinocandins (Garcia-Effron et al. 2008);
therefore, compounds with echinocandin-potentiator
effect are needed against biofilms formed by this species.
C. albicans cells with decreased chitin content are asso-
ciated with increased susceptibility against echinocandins;
which can explain the synergizing effect of nikkomycin Z
(Plaine et al. 2008). The observed synergistic interaction
between echinocandins and nikkomycin Z against C. albi-
cans biofilms may be attributable to the simultaneous
inhibition of synthesis of glucan and chitin components
in cell wall leading to higher osmotic stress and cell lysis
(Plaine et al. 2008; Cheung and Hui 2017). Our fluores-
cent images support this hypothesis because there were
no filamentous elements following exposure to echinocan-
dins with nikkomycin Z. Furthermore, the number of
viable cells was low, and the structure of the biofilm was





Figure 2 LIVE/DEAD fluorescence imaging of
one Candida albicans (CA1) (a, c, e and g)
and one Candida parapsilosis (CP1) (b, d, f
and h) representative isolates after
micafungin exposure with (g and h) and
without (e and f) nikkomycin Z. Pictures a
and b show the untreated C. albicans and
Candida parapsilosis biofilms respectively;
while picture c and d demonstrate the
nikkomycin Z-exposed biofilms for C. albicans
(c) and C. parapsilosis (d) respectively. Live
cells (green) and nonviable cells (red) were
stained with Syto9 and propidium iodide
respectively. All images show typical fields of
view. Scale bars represent 10 lm. [Colour
figure can be viewed at wileyonlinelibrary.com]
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Concerning echinocandin-resistant C. albicans biofilms,
synergy was observed similar to the planktonic results by
Cheung and Hui (2017). Their study described a synergis-
tic effect between nikkomycin Z and micafungin or
anidulafungin (FICI 038) in line with the findings of our
reported FICIs (FICIs were 0245 and 0037 for caspo-
fungin and micafungin respectively) (Cheung and Hui
2017).
Unfortunately, the lack of data dealing with detailed
molecular changes in echinocandin- or nikkomycin Z-ex-
posed C. parapsilosis cell wall precludes any explanation
regarding the background of synergism between
echinocandins and nikkomycin Z. However, we hypothe-
size that the synergistic effect observed against C. parap-
silosis may be caused by understudied specific cell wall
stress pathways of C. parapsilosis.
Interestingly, micafungin showed higher synergism com-
bined with nikkomycin Z both against C. albicans and C.
parapsilosis biofilms compared to the combination of caspo-
fungin and nikkomycin Z. This striking synergy observed
can be explained by micafungin-induced extended produc-
tion of reactive oxygen species and increased apoptosis as
reported by Shirazi and Kontoyiannis (2015). Our study was
subject to two limitations. First, we included only one fks
mutant C. albicans isolates. Second, we did not evaluate the
effect of anidulafungin combined with nikkomycin Z.
Despite these limitations, the potentiator effect of nikkomy-
cin Z in combination with caspofungin or micafungin
against C. albicans or C. parapsilosis biofilms is unquestion-
able, which supports their common use in alternative treat-
ment even in antifungal lock therapy.
In conclusion, the present study is the first analysis
examining the interaction of echinocandins and nikkomy-
cin Z against biofilms. We have shown that nikkomycin Z
is capable of causing a synergy in combination with
caspofungin or micafungin against C. albicans and C.
parapsilosis biofilms. This synergy was more pronounced
for micafungin combined with nikkomycin Z. It is high-
lighted that synergistic interaction was observed not only
for echinocandin-susceptible strains but also for the
echinocandin-resistant C. albicans isolate. Our results sup-
port the simultaneous use of nikkomycin Z and caspo-
fungin or micafungin in alternative therapies as antifungal
lock therapy. Nevertheless, further animal experiments are




Five clinical C. albicans and five C. parapsilosis sensu
stricto isolates derived from bloodstream infections were
examined. All were identified using MALDI/TOF (matrix-
assisted laser desorption/ionization/time of flight) analysis
(Microflex, Bruker Daltronics, Bremen, Germany). Fur-
thermore, identification of C. parapsilosis sensu stricto iso-
lates was also confirmed using molecular biology method
(Tavanti et al. 2005). One echinocandin-resistant C. albi-
cans isolate (DPL18, FKS F641S) was also included in the
study.
Minimal inhibitory concentration (MIC) determination
of planktonic cells
Planktonic MIC determination was performed in accor-
dance with the protocol M27-A3 of Clinical Laboratory
Standards Institute (Clinical and Laboratory Standards
Institute 2008). MICs of caspofungin (Sigma, Budapest,
Hungary), micafungin (Abmole Bioscience Inc., Houston)
and nikkomycin Z (Sigma, Budapest, Hungary) were
determined in RPMI-1640 (with L-glutamine and without
bicarbonate, pH 70 with MOPS; Sigma, Budapest, Hun-
gary). The tested drug concentrations ranged from 0015
to 8 mg l1 for caspofungin and micafungin, while nik-
komycin Z concentrations ranged from 006 to
32 mg l1. MICs were determined as the lowest drug
concentration that produces at least 50% growth reduc-
tion compared to the growth control. MICs represent
three independent experiments per isolate and are
expressed as median.
Biofilm development
Candida albicans and C. parapsilosis 1-day-old biofilms
were prepared as described previously (Kovacs et al.
2016). Briefly, isolates were suspended in RPMI-1640
broth in concentration of 1 9 106 cells per ml and ali-
quots of 100 µl were inoculated onto flat-bottom 96-well
sterile microtitre plates (TPP, Trasadingen, Switzerland)
and then incubated statically at 37°C for 24 h (Kovacs
et al. 2016).
Antifungal susceptibility testing of biofilms
The examined echinocandin concentrations for MIC
determination ranged from 0015 to 1 mg l1, from 025
to 16 mg l1 and from 8 to 512 mg l1 for echinocan-
din-susceptible C. albicans isolates, echinocandin-resistant
C. albicans strain and C. parapsilosis isolates respectively.
The examined nikkomycin Z concentrations ranged from
003 to 8 mg l1 in case of both species. The biofilms
were washed three times with sterile physiological saline.
Afterwards, MIC determination was performed in RPMI-
1640 using the XTT-assay as described previously (Kovacs
et al. 2016). The percentage change in metabolic activity
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was calculated on the basis of absorbance (A) as 100-
% 9 (Awell  Abackground)/(Adrug-free well  Abackground).
MICs of biofilms were defined as the lowest drug concen-
tration resulting in at least 50% metabolic activity reduc-
tion compared to growth control cells (Kovacs et al.
2016). MICs represent three independent experiments per
isolate and are expressed as median value.
Evaluation of interactions by fractional concentration
index (FICI) and Bliss independence model
Interactions between echinocandins and nikkomycin Z were
assessed using two-dimensional broth microdilution
checkerboard assay for sessile cells. Interactions were then
analysed using FICI determination and Bliss independence
model (Van Dijck et al. 2018). The tested concentration
ranges were the same as described above for biofilm MIC
determination. FICIs was calculated using the following for-








MICs of drugs A and B when used alone, and MICA
comb
and MICB
comb represent the MIC values of drugs A and B
in combination at isoeffective combinations respectively
(Kovacs et al. 2016; Van Dijck et al. 2018). FICI was deter-
mined as the lowest ΣFIC. MIC values of the drugs alone
and of all isoeffective combinations were determined as the
lowest concentration resulting in at least 50% metabolic
activity reduction compared to the untreated control bio-
films. If the obtained MIC value is higher than the highest
tested drug concentration, the next highest twofold concen-
tration was considered as MIC. FICI values of ≤05 were
defined as synergistic, between >05 and 4 as indifferent,
and >4 as antagonistic. FICIs were determined in three inde-
pendent experiments and median values were presented
(Kovacs et al. 2016; Van Dijck et al. 2018).
To further analyse echinocandin-nikkomycin Z inter-
actions, MacSynergy II was used, which employs the
Bliss independence algorithm to determine synergy. The
Bliss independence model is defined by the equa-
tion Eab = Ea + Eb  (EaEb), where Eab is the additive
effect of compounds a and b as predicted by their indi-
vidual effects (Ea and Eb) (Kovacs et al. 2016; Lai
et al. 2016). The obtained E values of each combina-
tion were presented on the z-axis in the three-dimen-
sional plot. Synergy and antagonism were expressed in
units of M2% which are analogous to the units for area
under a dose–response curve in the two-dimensional
graph. Synergy or antagonism is significant if the inter-
action volumes are greater than 25 M2% (log volume
>2) or lower than 25 M2% (log volume <2) respec-
tively (Kovacs et al. 2016; Lai et al. 2016). When a
small number of drug concentration pairs show indif-
ferent or antagonistic interaction in a generally
synergistic combination, the applied terminology is ‘syn-
ergy for most combinations’. The synergy volumes were
calculated at the 95% level of confidence (Kovacs et al.
2016; Lai et al. 2016).
Biofilm viability assay with and without nikkomycin Z
All C. albicans and one C. parapsilosis isolates were exam-
ined for LIVE/DEAD BacLightTM viability assay and pic-
tures from one-one representative isolate were presented
(CA1 and CP1 for C. albicans and C. parapsilosis respec-
tively). Biofilms were grown on the surface of 8 well Per-
manex slide for 24 h (Lab-Tek Chamber SlideTM System,
VWR, Debrecen, Hungary). After a one-day incubation per-
iod, the preformed biofilms were washed three times using
sterile physiological saline and various drug concentrations
were added to the samples as follows: C. albicans: 8 mg l1
nikkomycin Z, 025 mg l1 caspofungin, 025 mg l1 mica-
fungin, 025 mg l1 caspofungin + 8 mg l1 nikkomycin Z,
025 mg l1 micafungin + 8 mg l1 nikkomycin Z; C. para-
psilosis: 8 mg l1 nikkomycin Z, 128 mg l1 caspofungin,
128 mg l1 micafungin, 128 mg l1 caspofungin + 8
mg l1 nikkomycin Z, 128 mg l1 micafungin + 8 mg l1
nikkomycin Z. These concentrations were chosen based on
the checkerboard results. After 24 h of antifungal treatment,
biofilms were washed with sterile physiological saline and
the ratio of viable and dead cells was evaluated using fluo-
rescent LIVE/DEAD BacLightTM viability kit (Thermo
Fisher Scientific, Waltham, MA) as described our previous
work (Nagy et al. 2018). Biofilms were stained for 15 min
in darkness at 37°C using Syto 9 (334 mmol l1 solution
in DMSO) and propidium iodide (20 mmol l1 solution in
DMSO) to examine viable and dead Candida cells respec-
tively (Basas et al. 2016). Fluorescent cells were studied
using a Zeiss AxioSkop 2 mot microscope (Jena, Germany)
coupled with a Zeiss AxioCam HRc camera (Jena, Ger-
many). Analysis of images was performed using Axiovision
4.8.2 (Jena, Germany).
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